title: Morbidity and mortality revisited: applying a new quality improvement paradigm in oncology.
authors.affiliation: Dana-Farber Cancer Institute; and Beth Israel Deaconess Medical Center, Boston, MA.
authors.forename: Daniel G
authors.initials: DG
authors.lastname: Stover
authors.affiliation: Dana-Farber Cancer Institute; and Beth Israel Deaconess Medical Center, Boston, MA jzerillo@bidmc.harvard.edu.
authors.forename: Jessica A
authors.initials: JA
authors.lastname: Zerillo
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D064146:Chemotherapy-Induced Febrile Neutropenia / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D003299:Cooperative Behavior; D019091:Critical Pathways; D004334:Drug Administration Schedule; D006801:Humans; D033183:Interdisciplinary Communication; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D008875:Middle Aged; D000067491:Near Miss, Healthcare; D010348:Patient Care Team; D058996:Quality Improvement / Q000592:standards*; D019984:Quality Indicators, Health Care / Q000592:standards*; D018570:Risk Assessment; D012307:Risk Factors; D061665:Time-to-Treatment; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents